Stoke Therapeutics, Inc. STOK Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $84.22M-34.2% | $127.98M-33.1% | $191.44M+68.6% | $113.56M-21.6% | ||
| $200.45M+125% | $88.92M+793% | $9.95M-91.4% | $116.04M+54.9% | ||
| $494K+559% | $75K-86.8% | $569K0.0% | $569K0.0% | ||
| —— | $1.71M— | —— | —— | ||
| $8.74M-21.4% | $11.12M-1.8% | $11.32M+3.5% | $10.93M+19.4% | ||
| $1.97M+181% | $700K+994% | $64K-89.1% | $588K+345% | ||
| $305.7M+31.3% | $232.76M+8.1% | $215.34M-11.8% | $244.07M+6.5% | ||
| $3.15M-19.5% | $3.91M-32.9% | $5.82M-12.8% | $6.68M+61.3% | ||
| $3.1M-28.6% | $4.35M-34.3% | $6.61M+39.1% | $4.75M-3.8% | ||
| $106.26M+256% | $29.82M— | —— | —— | ||
| $418.43M+54.1% | $271.56M+18.9% | $228.34M-10.8% | $256.07M+7.2% | ||
| $4.94M+97.7% | $2.5M+47.4% | $1.7M+121% | $766K-67.9% | ||
| $6.96M— | —— | $33.07M-10.3% | $36.86M— | ||
| $3.01M+29.5% | $2.32M+12.6% | $2.06M-12.6% | $2.36M+56.5% | ||
| $57.88M+44.5% | $40.06M+30.0% | $30.82M-1.8% | $31.39M+83.2% | ||
| $4.15M-13.1% | $4.77M-30.2% | $6.84M+34.7% | $5.08M-27.2% | ||
| $1.14M-54.0% | $2.48M-49.3% | $4.88M+64.6% | $2.97M-24.8% | ||
| $8.1M+227% | $2.48M-93.5% | $37.96M-4.7% | $39.82M+908% | ||
| $65.98M+55.1% | $42.53M-38.2% | $68.78M-3.4% | $71.22M+238% | ||
| $5K0.0% | $5K0.0% | $5K+25.0% | $4K0.0% | ||
| $849.62M+18.0% | $720M+28.2% | $561.43M+16.2% | $483.17M+16.7% | ||
| -$497.72M-1.4% | -$490.83M-22.1% | -$401.85M-35.2% | -$297.15M-51.5% | ||
| $543K+460% | -$151K-529% | -$24K+98.0% | -$1.18M-599% | ||
| $352.46M+53.9% | $229.02M+43.5% | $159.57M-13.7% | $184.85M-15.1% | ||
| $418.43M+54.1% | $271.56M+18.9% | $228.34M-10.8% | $256.07M+7.2% | ||
| $200.45M+125% | $88.92M+793% | $9.95M-91.4% | $116.04M+54.9% | ||
| $4.39M+91.1% | $2.3M-10.3% | $2.56M-13.3% | $2.96M+33.3% | ||
| $3.1M-28.6% | $4.35M-34.3% | $6.61M+39.1% | $4.75M-3.8% | ||
| $106.26M+256% | $29.82M— | —— | —— | ||
| $3.1M-28.6% | $4.35M-34.3% | $6.61M+39.1% | $4.75M-3.8% | ||
| $3.1M-28.6% | $4.35M-34.3% | $6.61M+39.1% | $4.75M-3.8% | ||
| $41.04M+121% | $18.57M+34.4% | $13.82M-12.3% | $15.75M+6.7% | ||
| $11.9M-37.3% | $18.99M+24.1% | $15.31M+2.9% | $14.88M— | ||
| $6.96M— | —— | $33.07M-10.3% | $36.86M— | ||
| $4.15M-13.1% | $4.77M-30.2% | $6.84M+34.7% | $5.08M-27.2% | ||
| $5K0.0% | $5K0.0% | $5K+25.0% | $4K0.0% | ||
| $1.97M+181% | $700K+994% | $64K-89.1% | $588K+345% | ||
| $8.74M-21.4% | $11.12M-1.8% | $11.32M+3.5% | $10.93M+57.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Stoke Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.99 — current assets exceed current liabilities.
- Where does Stoke Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.